Libramont-Chevigny

• REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis. Pending
  2024-519298-21-00 5 Cancer-Associated Thrombosis (CAT).
• Study to assess the efficacy and safety of Rina-S plus standard of care compared to standard of care for maintenance treatment of participan … Pending
  2025-522167-15-00 5 Ovarian Cancer Platinum-Sensitive Ovarian Cancer (PSOC)
• A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell L … Pending
  2025-522818-23-00 5 Small Cell Lung Cancer (SCLC)
• First trial in humans testing the safety and efficacy of IMGN151 in women with recurrent gynaecological cancers Recruiting
  2023-506842-22-00 7 2025-05-19 Recurrent endometrial cancer, recurrent epithelial ovarian, fallopian
• Beamion BCGC-1: A study to find a suitable dose of zongertinib used alone and in combination with other treatments to test whether it helps … Recruiting
  2023-509566-38-00 9 2024-08-05 gastroesophageal junction adenocarcinoma
• Evaluation of epithelial ovarian, primary peritoneal, or fallopian tube cancer treatment in first recurrance using platinum-based chemothera … Recruiting
  2022-501220-14-00 4 2023-10-17 epithelial ovarian, primary peritoneal, or fallopian tube cancer
• AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (TREVI-OC-01) Recruiting
  2025-520466-22-00 5 2026-04-29 Advanced Platinum-resistant Epithelial Ovarian Cancer
• A trial to learn how effective and safe datopotamab deruxtecan (Dato-DXd) is compared to docetaxel and how well Dato-DXd works in adults wit … Recruiting
  2024-520101-39-00 5 2026-04-01 TROP2 NMR-positive advanced or metastatic non-squamous non-small cell
• A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg … Recruiting
  2025-523083-21-00 5 2025-12-08 PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-line Treatment of PD-L1-high Metastatic Non-small Cell Lung … Recruiting
  2024-517780-24-00 5 2025-09-18 Lung Cancer
• Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamo … Recruiting
  2023-506308-24-00 10 2024-05-22 Recurrent or metastatic head and neck squamous cell carcinoma
• Efficacy and safety of conventional neoadjuvant therapy versus total neoadjuvant therapy in older patients with locally advanced rectal canc … Recruiting
  2023-506703-26-00 5 2024-02-07 locally advanced rectal cancer
• A Study Evaluating the Overall Survival of Patients with Extensive Stage Small Cell Lung Cancer Receiving Trilaciclib or Placebo prior to To … Recruiting
  2022-502357-34-00 5 2023-09-27 Extensive Stage Small Cell Lung Cancer
• A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit … Ended recruitment
  2023-505928-59-00 5 2024-04-15 Triple Negative or Hormone Receptor low/HER2-negative Breast Cancer
• A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic B … Ended recruitment
  2022-503114-23-00 3 2023-12-19 Breast Cancer
• A study in metastatic breast cancer patients receiving eftilagimod alpha or placebo in combination with a standard chemotherapy (paclitaxel) Ended recruitment
  2024-511023-34-00 10 2023-05-05 HER2-neg/low metastatic breast cancer
• Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 … Ended recruitment
  2023-507187-39-00 5 2023-03-23 High-Risk Non-muscle-invasive Bladder Cancer
• Study of ceralasertib plus durvalumab versus docetaxel for patients with advanced or metastatic non-small cell lung cancer Ended recruitment
  2023-509429-37-00 5 2022-10-03 Advanced or Metastatic Non-Small Cell Lung Cancer
• Genetic vaccine for the treatment of microsatellite unstable solid tumors Ended recruitment
  2024-514723-42-00 9 2022-05-05 Locally advanced unresectable or metastatic, microsatellite instabilit
• Evaluation of two maintenance therapies (OSE2101 alone or in combination with pembrolizumab) versus best supportive care in patient with pla … Ended recruitment
  2024-516096-32-00 4 2021-08-05 Platinum sensitive recurrent ovarian cancer
• DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer Ended recruitment
  2023-509865-19-00 5 2021-04-30 Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
• A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed … Ended recruitment
  2022-502746-27-00 5 2020-08-21 Endometrial Cancer
• A trial to learn how camizestrant (AZD9833) works compared to fulvestrant and how safe it is in women with advanced breast cancer who have g … Ended recruitment
  2023-504974-40-00 4 2020-04-24 Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer
• A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea … Ended recruitment
  2023-510357-42-00 5 2019-05-22 hormone receptor (HR)-positive, HER2-negative, early breast cancer (EB

Showing 1–24 of 33 trials